Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to licence technology targeting the MUC1-C oncoprotein. This agreement allows Hillstream to leverage Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumours, which represents a major unmet need for patients. Under an exclusive option agreement which, if converted into an exclusive licence agreement, will allow Hillstream to develop anti-MUC1-C antibodies to supply Hillstream's Quatramer-based lead candidate. HSB-1216 targets CSC by inducing ferroptosis. This approach, combineing HSB-1216 for conjugation with MUC1-C antibodies, is highly synergistic in eliminating CSCs, effective for long-term responses and treatments. MUC1-C is effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC). MUC1-C is considered necessary for multiple hallmarks of the cancer cell, including (i) the persister cell (PC) state, (ii) drug resistance, (iii) immunosuppression, and (iv) poor clinical outcomes
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!